Lysophosphatidic acid mediates imiquimod‐induced psoriasis‐like symptoms by promoting keratinocyte proliferation through lpar1/rock2/pi3k/akt signaling pathway

Psoriasis is a chronic inflammatory skin disease. Recently, lysophosphatidic acid (LPA)/LPAR5 signaling has been reported to be involved in both NLRP3 inflammasome activation in macrophages and keratinocyte activation to produce inflammatory cytokines, contributing to psoriasis pathogenesis. However, the effect and molecular mechanisms of LPA/LPAR signaling in keratinocyte proliferation in psoriasis remain unclear. In this study, we investigated the effects of LPAR1/3 inhibition on imiquimod (IMQ)‐induced psoriasis‐like mice. Treatment with the LPAR1/3 antagonist, ki16425, alleviated skin symptoms in IMQ‐induced psoriasis‐like mouse models and decreased keratinocyte proliferation in the lesion. It also decreased LPA‐induced cell proliferation and cell cycle progression via increased cyclin A2, cyclin D1, cyclin‐dependent kinase (CDK)2, and CDK4 expression and decreased p27^Kip1 expression in HaCaT cells. LPAR1 knockdown in HaCaT cells reduced LPA‐induced proliferation, suppressed cyclin A2 and CDK2 expression, and restored p27^Kip1 expression. LPA increased Rho‐associated protein kinase 2 (ROCK2) expression and PI3K/AKT activation; moreover, the pharmacological inhibition of ROCK2 and PI3K/AKT signaling suppressed LPA‐induced cell cycle progression. In conclusion, we demonstrated that LPAR1/3 antagonist alleviates IMQ‐induced psoriasis‐like symptoms in mice, and in particular, LPAR1 signaling is involved in cell cycle progression via ROCK2/PI3K/AKT pathways in keratinocytes.